Nasdaq · Healthcare
PROCEPT BioRobotics Corp (PRCT)
As-reported financials and recent SEC filings for PROCEPT BioRobotics Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$308.1M
Net income
$-95.6M
Net margin
-31.0%
Diluted EPS
$-1.72
ROE
-26.1%
P/E (TTM)
—
Market cap
$1.28B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M | $15.9M |
| Operating income | $-103.9M | $-96.6M | $-109.2M | $-80.7M | $-54.2M |
| Net income | $-95.6M | $-91.4M | $-105.9M | $-87.2M | $-59.9M |
| Diluted EPS | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-1.21 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →Go deeper on PRCT
Search PROCEPT BioRobotics Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.